Actively Recruiting
Observational Multicenter Study in Patients Receiving Chemotherapy and Amivantamab for Metastatic Non-small Cell Lung Cancer as Part of an Early Access Program
Led by GFPC Investigation · Updated on 2026-05-01
100
Participants Needed
16
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are studying adults with metastatic non-small cell lung cancer (NSCLC) who have specific mutations in the EGFR gene. The study aims to understand how well the combination of amivantamab and platinum-based chemotherapy works and how safe it is in real-life settings. There are two groups: one receiving this combination as their first treatment for an EGFR exon 20 insertion mutation, and another receiving it after prior treatment with osimertinib for EGFR exon 19 or 21 mutations. This observational study does not involve new treatments but collects information from people receiving amivantamab and chemotherapy through an early access program. Group A includes those treated initially with this combination, while Group B includes those treated after osimertinib. Participants continue their usual care and the study gathers medical data without extra tests or procedures. The study runs from March 21, 2024, to October 21, 2025. Participants will be followed by their regular oncologist, and the study will collect data on how long the treatment prevents cancer progression or death over a two-year period. Researchers will also monitor overall survival, response rates, side effects, treatment duration, and progression details. No additional visits or procedures are required beyond normal medical care, and the study uses information from standard clinical evaluations and records.
CONDITIONS
Brief Title
Observational Multicenter Study in Patients Receiving Chemotherapy and Amivantamab for Metastatic Non-small Cell Lung Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patient over 18 years old
- Metastatic non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion treated with amivantamab and platinum-based chemotherapy as first-line treatment via early access (Cohort A)
- Metastatic NSCLC with EGFR exon 19 or 21 mutation treated with amivantamab and platinum-based chemotherapy after osimertinib, with or without chemotherapy, via early access (Cohort B)
- Covered by the French National Health Insurance or an approved third-party payer
- Does not object to the collection of personal data for research purposes
You will not qualify if you...
- Under legal guardianship or subject to protective legal measures
- Explicitly refuses collection or use of personal data for research purposes
- Not enrolled, managed, or followed at the investigating site by a qualified investigator
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 2 years
Participants who receive amivantamab with platinum-based chemotherapy as part of an early access program are observed to collect data on treatment outcomes and disease progression.
Visits scheduled as per local practice during treatment and follow-up
Trial Site Locations
Total: 16 locations
1
CH du Pays d Aix - Service des Maladies Respiratoires
Aix-en-Provence, France, 13616
Actively Recruiting
2
APHP Hôpital Avicennes
Bobigny, France, 93000
Actively Recruiting
3
Hôpital Louis Pradel
Bron, France, 69500
Active, Not Recruiting
4
Pneumologie Centre François Baclesse
Caen, France, 14000
Active, Not Recruiting
5
Pneumologie Centre Hospitalier Intercommunal de Créteil
Créteil, France, 94010
Actively Recruiting
6
Hôpital A. Mignot
Le Chesnay, France, 78157
Actively Recruiting
7
Pneumologie Hôpital Calmette
Lille, France, 59000
Actively Recruiting
8
Pneumologie Hôpital privé Jean Mermoz
Lyon, France, 69085
Actively Recruiting
9
Centre Léon Bérard
Lyon, France, 69373
Actively Recruiting
10
Hôpital Nord
Marseille, France, 13915
Actively Recruiting
11
CHRU de Nancy
Nancy, France, 54000
Active, Not Recruiting
12
Centre Antoine Lacassagne
Nice, France, 06149
Active, Not Recruiting
13
Institut Curie
Paris, France, 75005
Active, Not Recruiting
14
CH de la Région d'Annecy - Service de Pneumologie
Pringy, France, 74374
Actively Recruiting
15
Pneumologie CHU St Etienne
Saint-Etienne, France, 42270
Actively Recruiting
16
CHU La Réunion Site Sud
Saint-Pierre, France, 97410
Actively Recruiting
Research Team
P
Prof. Laurent Greillier
S
Soizic Ferlandin
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here